Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX) from its SEC filings: 2025 revenue $10.0 million (-6% vs the year before), net margin -1136%, free cash flow -$83.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $10.0 million |
| Revenue growth | -6% |
| Net income | -$113.6 million |
| Net margin | -1136.2% |
| Free cash flow | -$83.3 million |
| Diluted EPS | $-1.83 |
| Cash | $27.8 million |
| Share count, 1 year | +2% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.